Optase Dry Eye Intense Drops — Class II drug recall D-0499-2026
Ongoing recall by SCOPE HEALTH, reported 2026-05-06, distributed nationwide. Lack of Assurance of Sterility
| Recall number | D-0499-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | SCOPE HEALTH, New York, NY, United States |
| Recall initiated | 2026-04-20 |
| Classified | 2026-04-28 |
| Reported by FDA | 2026-05-06 |
| Distributed | Nationwide (US) |
| Reason classes | sterility |
| NDC | 72972-0002, 72972-0002-01 |
| Lot numbers | 1X57, 1X70, 1X84, 2V13, 2V14, 2V15, 3V35, 3V36, 3V37, 5V45, 5V46, 8T98, 9T31, 9T32, 9V12 |
Product
Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope Health Inc., 79 Madison Ave., 8th Floor, New York, NY 10016, USA, NDC 72972-002-01.
Reason for recall
Lack of Assurance of Sterility
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0499-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.